aTyr Investors Face Dec. 8 Deadline in Securities Suits Over Efzofitimod Trial Failure

Rival law firms seek to lead the case, courting shareholders from differing class periods.

Overview

Notices from Hagens Berman, Rosen, Schall, Gross, Glancy Prongay & Murray, and Faruqi & Faruqi urge investors to move for lead-plaintiff status by Dec. 8.
Complaints allege aTyr misled the market about Efzofitimod’s efficacy and the EFZO‑FIT forced‑taper design, including claims about complete steroid withdrawal.
Proposed class periods vary, with some firms using Nov. 7, 2024 through Sept. 12, 2025 and others Jan. 16, 2025 through Sept. 12, 2025.
The litigation follows a Sept. 15 disclosure that the Phase 3 EFZO‑FIT study missed its primary endpoint, which was followed by an 83% one‑day stock drop.
No class has been certified, and aTyr has said it plans to consult the FDA on potential next steps for Efzofitimod.